Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

Currently, renal cell carcinoma is characterized by encouraging benefits from immunotherapy that have led to significant results in treatment outcome. The approval of nivolumab primarily as second-line monotherapy and, more recently, the approval of new combination therapies as first-line treatment...

Full description

Bibliographic Details
Main Authors: Giuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, Giorgia Gurioli, Lorena Rossi, Valentina Gallà, Maria Concetta Cursano, Nicole Brighi, Cristian Lolli, Cecilia Menna, Alberto Farolfi, Salvatore Luca Burgio, Amelia Altavilla, Giovanni Martinelli, Ugo De Giorgi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
CAR (chimeric antigen receptor) T cells
RCC
immunotherapy
inflammation
toxicity
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.565857/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.565857/full

Similar Items